{
  "symbol": "AMGN",
  "year": 2023,
  "Period": "Y2023",
  "report_type": "K10",
  "metrics": {
    "mdna_sentiment": 0.0,
    "outlook_sentiment": 0.1831,
    "forward_ratio": 1.0,
    "hedge_ratio": 0.189
  },
  "top_positive": [
    {
      "sent": "F-45 Impact of hedging transactions The following tables summarize the amounts recorded in income and expense line items and the effects thereon from fair value and cash flow hedging, including discontinued hedging relationships (in millions): Year ended December 31, 2022 Product sales Other (expense) income, net Interest expense, net Total amounts recorded in income and (expense) line items presented in the Consolidated Statements of Income $ 24,801 $ ( 814 ) $ ( 1,406 ) The effects of cash flow and fair value hedging: Gains (losses) on cash flow hedging relationships reclassified out of AOCI: Foreign currency forward contracts $ 231 $ \u2014 $ \u2014 Cross-currency swap contracts $ \u2014 $ ( 233 ) $ \u2014 Gains (losses) on fair value hedging relationships\u2014interest rate swap agreements: Hedged items (1) $ \u2014 $ \u2014 $ 716 Derivatives designated as hedging instruments $ \u2014 $ \u2014 $ ( 636 ) Year ended December 31, 2021 Product sales Other (expense) income, net Interest expense, net Total amounts recorded in income and (expense) line items presented in the Consolidated Statements of Income $ 24,297 $ 259 $ ( 1,197 ) The effects of cash flow and fair value hedging: Losses on cash flow hedging relationships reclassified out of AOCI: Foreign currency forward contracts $ ( 8 ) $ \u2014 $ \u2014 Cross-currency swap contracts $ \u2014 $ ( 245 ) $ \u2014 Gains (losses) on fair value hedging relationships\u2014interest rate swap agreements: Hedged items (1) $ \u2014 $ \u2014 $ 281 Derivatives designated as hedging instruments $ \u2014 $ \u2014 $ ( 192 ) Year ended December 31, 2020 Product sales Other (expense) income, net Interest expense, net Total amounts recorded in income and (expense) line items presented in the Consolidated Statements of Income $ 24,240 $ 256 $ ( 1,262 ) The effects of cash flow and fair value hedging: Gains on cash flow hedging relationships reclassified out of AOCI: Foreign currency forward contracts $ 178 $ \u2014 $ \u2014 Cross-currency swap contracts $ \u2014 $ 323 $ \u2014 Gains (losses) on fair value hedging relationships\u2014interest rate swap agreements: Hedged items (1) $ \u2014 $ \u2014 $ 315 Derivatives designated as hedging instruments $ \u2014 $ \u2014 $ ( 204 ) __________ (1) Gains on h\nonly if an event of default or termination, as defined, were to occur.",
      "score": 0.9939
    },
    {
      "sent": "(a) (b) (c) Plan category Number of securities to be issued upon exercise of outstanding options and rights Weighted-average exercise price of outstanding options and rights Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a)) Equity compensation plans approved by Amgen security holders: Amended and Restated 2009 Equity Incentive Plan (1) 10,235,620 $ 207.29 15,255,297 Amended and Restated 1991 Equity Incentive Plan (2) 2,191 Amended and Restated Employee Stock Purchase Plan 4,180,287 Total approved plans 10,237,811 207.29 19,435,584 Equity compensation plan not approved by Amgen security holders: Amgen Profit Sharing Plan for Employees in Ireland (3) 222,310 Total unapproved plans \u2014 \u2014 222,310 Total all plans 10,237,811 $ 207.29 19,657,894 (1) The Amended 2009 Plan employs a fungible share-counting formula for determining the number of shares available for issuance under the plan.",
      "score": 0.9884
    },
    {
      "sent": "(a) (b) (c) Plan category Number of securities to be issued upon exercise of outstanding options and rights Weighted-average exercise price of outstanding options and rights Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a)) Equity compensation plans approved by Amgen security holders: Amended and Restated 2009 Equity Incentive Plan (1) 10,235,620 $ 207.29 15,255,297 Amended and Restated 1991 Equity Incentive Plan (2) 2,191 Amended and Restated Employee Stock Purchase Plan 4,180,287 Total approved plans 10,237,811 207.29 19,435,584 Equity compensation plan not approved by Amgen security holders: Amgen Profit Sharing Plan for Employees in Ireland (3) 222,310 Total unapproved plans \u2014 \u2014 222,310 Total all plans 10,237,811 $ 207.29 19,657,894 (1) The Amended 2009 Plan employs a fungible share-counting formula for determining the number of shares available for issuance under the plan.",
      "score": 0.9884
    }
  ],
  "top_negative": [
    {
      "sent": "17 Molecule Investigational indication Phase 3 programs AMJEVITA Interchangeability Bemarituzumab GEJ adenocarcinoma BLINCYTO Ph-negative B-cell precursor acute lymphoblastic leukemia EVENITY Male osteoporosis KYPROLIS Weekly dosing for relapsed multiple myeloma LUMAKRAS/LUMYKRAS Advanced colorectal cancer Nplate Chemotherapy-induced thrombocytopenia Olpasiran Cardiovascular disease Otezla Genital psoriasis; Palmoplantar pustulosis Repatha Cardiovascular disease Rocatinlimab Atopic dermatitis TEZSPIRE Chronic rhinosinusitis with nasal polyps; Eosinophilic esophagitis; Severe asthma ABP 654 Investigational biosimilar to STELARA (ustekinumab) ABP 938 Investigational biosimilar to EYLEA (aflibercept) ABP 959 Investigational biosimilar to SOLIRIS (eculizumab) Phase 2 programs Efavaleukin alfa Systemic lupus erythematosus; Ulcerative colitis LUMAKRAS/LUMYKRAS NSCLC monotherapy; Other solid tumors with KRAS G12C mutations Ordesekimab Celiac disease Rozibafusp alfa Systemic lupus erythematosus Tarlatamab Small cell lung cancer TEZSPIRE Chronic obstructive pulmonary disease; Chronic spontaneous urticaria AMG 133 Obesity Phase 1 programs Acapatamab Prostate cancer Bemarituzumab NSCLC and other tumors Emirodatamab Acute myeloid leukemia Latikafusp Solid tumors Tarlatamab Neuroendocrine prostate cancer AMG 104 Asthma AMG 119 Small-cell lung cancer AMG 176 Hematologic malignancies AMG 193 Solid tumors AMG 199 Solid tumors AMG 340 Prostate cancer AMG 404 Solid tumors AMG 509 Prostate cancer AMG 609 Nonalcoholic steatohepatitis AMG 650 Solid tumors AMG 651 Colorectal cancer AMG 786 Obesity AMG 794 Solid tumors AMG 994 Solid tumors 18 Phase\u00a03 Clinical trials investigate the short- and long-term safety and efficacy of our product candidates, compared to commonly used treatments, in a large number of patients who have the disease or condition under study.",
      "score": -0.9833
    },
    {
      "sent": "17 Molecule Investigational indication Phase 3 programs AMJEVITA Interchangeability Bemarituzumab GEJ adenocarcinoma BLINCYTO Ph-negative B-cell precursor acute lymphoblastic leukemia EVENITY Male osteoporosis KYPROLIS Weekly dosing for relapsed multiple myeloma LUMAKRAS/LUMYKRAS Advanced colorectal cancer Nplate Chemotherapy-induced thrombocytopenia Olpasiran Cardiovascular disease Otezla Genital psoriasis; Palmoplantar pustulosis Repatha Cardiovascular disease Rocatinlimab Atopic dermatitis TEZSPIRE Chronic rhinosinusitis with nasal polyps; Eosinophilic esophagitis; Severe asthma ABP 654 Investigational biosimilar to STELARA (ustekinumab) ABP 938 Investigational biosimilar to EYLEA (aflibercept) ABP 959 Investigational biosimilar to SOLIRIS (eculizumab) Phase 2 programs Efavaleukin alfa Systemic lupus erythematosus; Ulcerative colitis LUMAKRAS/LUMYKRAS NSCLC monotherapy; Other solid tumors with KRAS G12C mutations Ordesekimab Celiac disease Rozibafusp alfa Systemic lupus erythematosus Tarlatamab Small cell lung cancer TEZSPIRE Chronic obstructive pulmonary disease; Chronic spontaneous urticaria AMG 133 Obesity Phase 1 programs Acapatamab Prostate cancer Bemarituzumab NSCLC and other tumors Emirodatamab Acute myeloid leukemia Latikafusp Solid tumors Tarlatamab Neuroendocrine prostate cancer AMG 104 Asthma AMG 119 Small-cell lung cancer AMG 176 Hematologic malignancies AMG 193 Solid tumors AMG 199 Solid tumors AMG 340 Prostate cancer AMG 404 Solid tumors AMG 509 Prostate cancer AMG 609 Nonalcoholic steatohepatitis AMG 650 Solid tumors AMG 651 Colorectal cancer AMG 786 Obesity AMG 794 Solid tumors AMG 994 Solid tumors 18 Phase\u00a03 Clinical trials investigate the short- and long-term safety and efficacy of our product candidates, compared to commonly used treatments, in a large number of patients who have the disease or condition under study.",
      "score": -0.9833
    },
    {
      "sent": "17 Molecule Investigational indication Phase 3 programs AMJEVITA Interchangeability Bemarituzumab GEJ adenocarcinoma BLINCYTO Ph-negative B-cell precursor acute lymphoblastic leukemia EVENITY Male osteoporosis KYPROLIS Weekly dosing for relapsed multiple myeloma LUMAKRAS/LUMYKRAS Advanced colorectal cancer Nplate Chemotherapy-induced thrombocytopenia Olpasiran Cardiovascular disease Otezla Genital psoriasis; Palmoplantar pustulosis Repatha Cardiovascular disease Rocatinlimab Atopic dermatitis TEZSPIRE Chronic rhinosinusitis with nasal polyps; Eosinophilic esophagitis; Severe asthma ABP 654 Investigational biosimilar to STELARA (ustekinumab) ABP 938 Investigational biosimilar to EYLEA (aflibercept) ABP 959 Investigational biosimilar to SOLIRIS (eculizumab) Phase 2 programs Efavaleukin alfa Systemic lupus erythematosus; Ulcerative colitis LUMAKRAS/LUMYKRAS NSCLC monotherapy; Other solid tumors with KRAS G12C mutations Ordesekimab Celiac disease Rozibafusp alfa Systemic lupus erythematosus Tarlatamab Small cell lung cancer TEZSPIRE Chronic obstructive pulmonary disease; Chronic spontaneous urticaria AMG 133 Obesity Phase 1 programs Acapatamab Prostate cancer Bemarituzumab NSCLC and other tumors Emirodatamab Acute myeloid leukemia Latikafusp Solid tumors Tarlatamab Neuroendocrine prostate cancer AMG 104 Asthma AMG 119 Small-cell lung cancer AMG 176 Hematologic malignancies AMG 193 Solid tumors AMG 199 Solid tumors AMG 340 Prostate cancer AMG 404 Solid tumors AMG 509 Prostate cancer AMG 609 Nonalcoholic steatohepatitis AMG 650 Solid tumors AMG 651 Colorectal cancer AMG 786 Obesity AMG 794 Solid tumors AMG 994 Solid tumors 18 Phase\u00a03 Clinical trials investigate the short- and long-term safety and efficacy of our product candidates, compared to commonly used treatments, in a large number of patients who have the disease or condition under study.",
      "score": -0.9833
    }
  ],
  "forward_snippets": [
    "A biotechnology pioneer, Amgen has grown to be one of the world\u2019s leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.",
    "A biotechnology pioneer, Amgen has grown to be one of the world\u2019s leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.",
    "Horizon has 12 marketed medicines and a pipeline with more than 20 development programs.",
    "Products/Pipeline Cardiometabolic Repatha \u2022 In 2022, we presented results from the Repatha FOURIER-OLE studies, two open label extension (OLE) studies (with 6,635 patients) to the Phase 3 FOURIER cardiovascular (CV) outcomes trial.",
    "A biotechnology pioneer, Amgen has grown to be one of the world\u2019s leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential."
  ],
  "curated_text": "Symbol: AMGN. Year: 2023. Period: Y2023. ReportType: K10. Section: Management Discussion and Analysis (MD&A). Key metrics include sentiment, forward outlook, and risk hedging.  Top positive sentences: F-45 Impact of hedging transactions The following tables summarize the amounts recorded in income and expense line items and the effects thereon from fair value and cash flow hedging, including discontinued hedging relationships (in millions): Year ended December 31, 2022 Product sales Other (expense) income, net Interest expense, net Total amounts recorded in income and (expense) line items presented in the Consolidated Statements of Income $ 24,801 $ ( 814 ) $ ( 1,406 ) The effects of cash flow and fair value hedging: Gains (losses) on cash flow hedging relationships reclassified out of AOCI: Foreign currency forward contracts $ 231 $ \u2014 $ \u2014 Cross-currency swap contracts $ \u2014 $ ( 233 ) $ \u2014 Gains (losses) on fair value hedging relationships\u2014interest rate swap agreements: Hedged items (1) $ \u2014 $ \u2014 $ 716 Derivatives designated as hedging instruments $ \u2014 $ \u2014 $ ( 636 ) Year ended December 31, 2021 Product sales Other (expense) income, net Interest expense, net Total amounts recorded in income and (expense) line items presented in the Consolidated Statements of Income $ 24,297 $ 259 $ ( 1,197 ) The effects of cash flow and fair value hedging: Losses on cash flow hedging relationships reclassified out of AOCI: Foreign currency forward contracts $ ( 8 ) $ \u2014 $ \u2014 Cross-currency swap contracts $ \u2014 $ ( 245 ) $ \u2014 Gains (losses) on fair value hedging relationships\u2014interest rate swap agreements: Hedged items (1) $ \u2014 $ \u2014 $ 281 Derivatives designated as hedging instruments $ \u2014 $ \u2014 $ ( 192 ) Year ended December 31, 2020 Product sales Other (expense) income, net Interest expense, net Total amounts recorded in income and (expense) line items presented in the Consolidated Statements of Income $ 24,240 $ 256 $ ( 1,262 ) The effects of cash flow and fair value hedging: Gains on cash flow hedging relationships reclassified out of AOCI: Foreign currency forward contracts $ 178 $ \u2014 $ \u2014 Cross-currency swap contracts $ \u2014 $ 323 $ \u2014 Gains (losses) on fair value hedging relationships\u2014interest rate swap agreements: Hedged items (1) $ \u2014 $ \u2014 $ 315 Derivatives designated as hedging instruments $ \u2014 $ \u2014 $ ( 204 ) __________ (1) Gains on h\nonly if an event of default or termination, as defined, were to occur. (a) (b) (c) Plan category Number of securities to be issued upon exercise of outstanding options and rights Weighted-average exercise price of outstanding options and rights Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a)) Equity compensation plans approved by Amgen security holders: Amended and Restated 2009 Equity Incentive Plan (1) 10,235,620 $ 207.29 15,255,297 Amended and Restated 1991 Equity Incentive Plan (2) 2,191 Amended and Restated Employee Stock Purchase Plan 4,180,287 Total approved plans 10,237,811 207.29 19,435,584 Equity compensation plan not approved by Amgen security holders: Amgen Profit Sharing Plan for Employees in Ireland (3) 222,310 Total unapproved plans \u2014 \u2014 222,310 Total all plans 10,237,811 $ 207.29 19,657,894 (1) The Amended 2009 Plan employs a fungible share-counting formula for determining the number of shares available for issuance under the plan. (a) (b) (c) Plan category Number of securities to be issued upon exercise of outstanding options and rights Weighted-average exercise price of outstanding options and rights Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a)) Equity compensation plans approved by Amgen security holders: Amended and Restated 2009 Equity Incentive Plan (1) 10,235,620 $ 207.29 15,255,297 Amended and Restated 1991 Equity Incentive Plan (2) 2,191 Amended and Restated Employee Stock Purchase Plan 4,180,287 Total approved plans 10,237,811 207.29 19,435,584 Equity compensation plan not approved by Amgen security holders: Amgen Profit Sharing Plan for Employees in Ireland (3) 222,310 Total unapproved plans \u2014 \u2014 222,310 Total all plans 10,237,811 $ 207.29 19,657,894 (1) The Amended 2009 Plan employs a fungible share-counting formula for determining the number of shares available for issuance under the plan. Top negative sentences: 17 Molecule Investigational indication Phase 3 programs AMJEVITA Interchangeability Bemarituzumab GEJ adenocarcinoma BLINCYTO Ph-negative B-cell precursor acute lymphoblastic leukemia EVENITY Male osteoporosis KYPROLIS Weekly dosing for relapsed multiple myeloma LUMAKRAS/LUMYKRAS Advanced colorectal cancer Nplate Chemotherapy-induced thrombocytopenia Olpasiran Cardiovascular disease Otezla Genital psoriasis; Palmoplantar pustulosis Repatha Cardiovascular disease Rocatinlimab Atopic dermatitis TEZSPIRE Chronic rhinosinusitis with nasal polyps; Eosinophilic esophagitis; Severe asthma ABP 654 Investigational biosimilar to STELARA (ustekinumab) ABP 938 Investigational biosimilar to EYLEA (aflibercept) ABP 959 Investigational biosimilar to SOLIRIS (eculizumab) Phase 2 programs Efavaleukin alfa Systemic lupus erythematosus; Ulcerative colitis LUMAKRAS/LUMYKRAS NSCLC monotherapy; Other solid tumors with KRAS G12C mutations Ordesekimab Celiac disease Rozibafusp alfa Systemic lupus erythematosus Tarlatamab Small cell lung cancer TEZSPIRE Chronic obstructive pulmonary disease; Chronic spontaneous urticaria AMG 133 Obesity Phase 1 programs Acapatamab Prostate cancer Bemarituzumab NSCLC and other tumors Emirodatamab Acute myeloid leukemia Latikafusp Solid tumors Tarlatamab Neuroendocrine prostate cancer AMG 104 Asthma AMG 119 Small-cell lung cancer AMG 176 Hematologic malignancies AMG 193 Solid tumors AMG 199 Solid tumors AMG 340 Prostate cancer AMG 404 Solid tumors AMG 509 Prostate cancer AMG 609 Nonalcoholic steatohepatitis AMG 650 Solid tumors AMG 651 Colorectal cancer AMG 786 Obesity AMG 794 Solid tumors AMG 994 Solid tumors 18 Phase\u00a03 Clinical trials investigate the short- and long-term safety and efficacy of our product candidates, compared to commonly used treatments, in a large number of patients who have the disease or condition under study. 17 Molecule Investigational indication Phase 3 programs AMJEVITA Interchangeability Bemarituzumab GEJ adenocarcinoma BLINCYTO Ph-negative B-cell precursor acute lymphoblastic leukemia EVENITY Male osteoporosis KYPROLIS Weekly dosing for relapsed multiple myeloma LUMAKRAS/LUMYKRAS Advanced colorectal cancer Nplate Chemotherapy-induced thrombocytopenia Olpasiran Cardiovascular disease Otezla Genital psoriasis; Palmoplantar pustulosis Repatha Cardiovascular disease Rocatinlimab Atopic dermatitis TEZSPIRE Chronic rhinosinusitis with nasal polyps; Eosinophilic esophagitis; Severe asthma ABP 654 Investigational biosimilar to STELARA (ustekinumab) ABP 938 Investigational biosimilar to EYLEA (aflibercept) ABP 959 Investigational biosimilar to SOLIRIS (eculizumab) Phase 2 programs Efavaleukin alfa Systemic lupus erythematosus; Ulcerative colitis LUMAKRAS/LUMYKRAS NSCLC monotherapy; Other solid tumors with KRAS G12C mutations Ordesekimab Celiac disease Rozibafusp alfa Systemic lupus erythematosus Tarlatamab Small cell lung cancer TEZSPIRE Chronic obstructive pulmonary disease; Chronic spontaneous urticaria AMG 133 Obesity Phase 1 programs Acapatamab Prostate cancer Bemarituzumab NSCLC and other tumors Emirodatamab Acute myeloid leukemia Latikafusp Solid tumors Tarlatamab Neuroendocrine prostate cancer AMG 104 Asthma AMG 119 Small-cell lung cancer AMG 176 Hematologic malignancies AMG 193 Solid tumors AMG 199 Solid tumors AMG 340 Prostate cancer AMG 404 Solid tumors AMG 509 Prostate cancer AMG 609 Nonalcoholic steatohepatitis AMG 650 Solid tumors AMG 651 Colorectal cancer AMG 786 Obesity AMG 794 Solid tumors AMG 994 Solid tumors 18 Phase\u00a03 Clinical trials investigate the short- and long-term safety and efficacy of our product candidates, compared to commonly used treatments, in a large number of patients who have the disease or condition under study. 17 Molecule Investigational indication Phase 3 programs AMJEVITA Interchangeability Bemarituzumab GEJ adenocarcinoma BLINCYTO Ph-negative B-cell precursor acute lymphoblastic leukemia EVENITY Male osteoporosis KYPROLIS Weekly dosing for relapsed multiple myeloma LUMAKRAS/LUMYKRAS Advanced colorectal cancer Nplate Chemotherapy-induced thrombocytopenia Olpasiran Cardiovascular disease Otezla Genital psoriasis; Palmoplantar pustulosis Repatha Cardiovascular disease Rocatinlimab Atopic dermatitis TEZSPIRE Chronic rhinosinusitis with nasal polyps; Eosinophilic esophagitis; Severe asthma ABP 654 Investigational biosimilar to STELARA (ustekinumab) ABP 938 Investigational biosimilar to EYLEA (aflibercept) ABP 959 Investigational biosimilar to SOLIRIS (eculizumab) Phase 2 programs Efavaleukin alfa Systemic lupus erythematosus; Ulcerative colitis LUMAKRAS/LUMYKRAS NSCLC monotherapy; Other solid tumors with KRAS G12C mutations Ordesekimab Celiac disease Rozibafusp alfa Systemic lupus erythematosus Tarlatamab Small cell lung cancer TEZSPIRE Chronic obstructive pulmonary disease; Chronic spontaneous urticaria AMG 133 Obesity Phase 1 programs Acapatamab Prostate cancer Bemarituzumab NSCLC and other tumors Emirodatamab Acute myeloid leukemia Latikafusp Solid tumors Tarlatamab Neuroendocrine prostate cancer AMG 104 Asthma AMG 119 Small-cell lung cancer AMG 176 Hematologic malignancies AMG 193 Solid tumors AMG 199 Solid tumors AMG 340 Prostate cancer AMG 404 Solid tumors AMG 509 Prostate cancer AMG 609 Nonalcoholic steatohepatitis AMG 650 Solid tumors AMG 651 Colorectal cancer AMG 786 Obesity AMG 794 Solid tumors AMG 994 Solid tumors 18 Phase\u00a03 Clinical trials investigate the short- and long-term safety and efficacy of our product candidates, compared to commonly used treatments, in a large number of patients who have the disease or condition under study. Forward-looking snippets: A biotechnology pioneer, Amgen has grown to be one of the world\u2019s leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential. A biotechnology pioneer, Amgen has grown to be one of the world\u2019s leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential. Horizon has 12 marketed medicines and a pipeline with more than 20 development programs. Products/Pipeline Cardiometabolic Repatha \u2022 In 2022, we presented results from the Repatha FOURIER-OLE studies, two open label extension (OLE) studies (with 6,635 patients) to the Phase 3 FOURIER cardiovascular (CV) outcomes trial. A biotechnology pioneer, Amgen has grown to be one of the world\u2019s leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential."
}